RATIONALE: In studies that address health-related quality of life (QoL) and survival, subjects who die are usually censored from QoL assessments. This practice tends to inflate the apparent benefits of interventions with a high risk of mortality. Assessing a composite QoL-death outcome is a potential solution to this problem. OBJECTIVES: To determine the effect of lung volume reduction surgery (LVRS) on a composite endpoint consisting of the occurrence of death or a clinically meaningful decline in QoL defined as an increase of at least eight points in the St. George's Respiratory Questionnaire total score from the National Emphysema Treatment Trial. METHODS: In patients with chronic obstructive pulmonary disease and emphysema randomized to receive medical treatment (n = 610) orLVRS (n = 608), we analyzed the survival to the composite endpoint, the hazard functions and constructed prediction models of the slope of QoL decline. MEASUREMENTS AND MAIN RESULTS: The time to the composite endpoint was longer in the LVRS group (2 years) than the medical treatment group (1 year) (P < 0.0001). It was even longer in the subsets of patients undergoing LVRS without a high risk for perioperative death and with upper-lobe-predominant emphysema. The hazard for the composite event significantly favored the LVRS group, although it was most significant in patients with predominantly upper-lobe emphysema. The beneficial impact of LVRS on QoL decline was most significant during the 2 years after LVRS. CONCLUSIONS:LVRS has a significant effect on the composite QoL-survival endpoint tested, indicating its meaningful palliative role, particularly in patients with upper-lobe-predominant emphysema.
RCT Entities:
RATIONALE: In studies that address health-related quality of life (QoL) and survival, subjects who die are usually censored from QoL assessments. This practice tends to inflate the apparent benefits of interventions with a high risk of mortality. Assessing a composite QoL-death outcome is a potential solution to this problem. OBJECTIVES: To determine the effect of lung volume reduction surgery (LVRS) on a composite endpoint consisting of the occurrence of death or a clinically meaningful decline in QoL defined as an increase of at least eight points in the St. George's Respiratory Questionnaire total score from the National Emphysema Treatment Trial. METHODS: In patients with chronic obstructive pulmonary disease and emphysema randomized to receive medical treatment (n = 610) or LVRS (n = 608), we analyzed the survival to the composite endpoint, the hazard functions and constructed prediction models of the slope of QoL decline. MEASUREMENTS AND MAIN RESULTS: The time to the composite endpoint was longer in the LVRS group (2 years) than the medical treatment group (1 year) (P < 0.0001). It was even longer in the subsets of patients undergoing LVRS without a high risk for perioperative death and with upper-lobe-predominant emphysema. The hazard for the composite event significantly favored the LVRS group, although it was most significant in patients with predominantly upper-lobe emphysema. The beneficial impact of LVRS on QoL decline was most significant during the 2 years after LVRS. CONCLUSIONS: LVRS has a significant effect on the composite QoL-survival endpoint tested, indicating its meaningful palliative role, particularly in patients with upper-lobe-predominant emphysema.
Authors: Anna Maria Ciccone; Bryan F Meyers; Tracey J Guthrie; Gail E Davis; Roger D Yusen; Stephen S Lefrak; G Alexander Patterson; Joel D Cooper Journal: J Thorac Cardiovasc Surg Date: 2003-03 Impact factor: 5.209
Authors: Roger D Yusen; Stephen S Lefrak; David S Gierada; Gail E Davis; Bryan F Meyers; G Alexander Patterson; Joel D Cooper Journal: Chest Date: 2003-04 Impact factor: 9.410
Authors: Alfred Fishman; Henry Fessler; Fernando Martinez; Robert J McKenna; Keith Naunheim; Steven Piantadosi; Gail Weinmann; Robert Wise Journal: N Engl J Med Date: 2001-10-11 Impact factor: 91.245
Authors: Antònia Domingo-Salvany; Rosa Lamarca; Montserrat Ferrer; Judith Garcia-Aymerich; Jordi Alonso; Miquel Félez; Ahmad Khalaf; Ramon M Marrades; Eduard Monsó; Joan Serra-Batlles; Josep M Antó Journal: Am J Respir Crit Care Med Date: 2002-09-01 Impact factor: 21.405
Authors: Wei Huang; Wen R Wang; Bo Deng; You Q Tan; Guang Y Jiang; Hai Jing Zhou; Yong He Journal: J Cardiothorac Surg Date: 2011-11-10 Impact factor: 1.637
Authors: J P Singer; P P Katz; A Soong; P Shrestha; D Huang; J Ho; M Mindo; J R Greenland; S R Hays; J Golden; J Kukreja; M E Kleinhenz; R J Shah; P D Blanc Journal: Am J Transplant Date: 2017-01-03 Impact factor: 8.086
Authors: Jonathan Paul Singer; Joan Chen; Patricia P Katz; Paul David Blanc; Marjorie Kagawa-Singer; Anita L Stewart Journal: Qual Life Res Date: 2014-12-04 Impact factor: 4.147
Authors: Zaid Zoumot; Samuel V Kemp; Suveer Singh; Stephen R Bicknell; William H McNulty; Nicholas S Hopkinson; Ewen T Ross; Pallav L Shah Journal: PLoS One Date: 2015-04-08 Impact factor: 3.240